Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A

Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A

SSZSE:300204
16.15
CNY
-0.34
(-2.06%)
-0.22EPS
11.07BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.91
2.32
2.66
2.95
2.9
1.68
1.45
0.9
1.23
1.14
0.77
0.67
0.45
0.39
Basic EPS, GAAP
0.23
0.41
0.45
0.54
0.55
0.28
0.06
-0.28
-0.29
-0.41
-0.84
-0.3
-0.16
-0.21
Free Cash Flow per Basic Share
0.19
0.41
0.44
0.39
0.47
0.15
-0.03
-0.34
-0.46
-0.48
-0.55
-0.18
-0.42
- -
Dividend per Share
0.11
0.05
0.15
0.14
0.18
0.25
0.69
- -
- -
- -
- -
- -
- -
0.01
Book Value per Share
2.79
3.22
3.51
3.97
4.62
5.16
3.44
3.33
3.26
2.85
2.14
1.94
1.72
3.71
Tangible Book Value per Share
2.64
3.09
3.39
3.86
4.51
5.02
3.28
3.07
3.03
2.58
1.89
1.58
1.21
3.18
Basic Weighted Avg Shares
467
471
469
476
478
479
455
475
474
481
475
483
486
480
Sales/Revenue/Turnover
893
1,093
1,248
1,403
1,388
806
661
425
584
549
364
325
220
187
Operating Margin (%)
11.23
14.92
18.3
18.67
18.15
11.86
-1.34
-41.23
-39.59
-40.62
-98.18
-10.51
-35.6
-47.51
Depreciation Expense
12
19
19
22
25
27
30
35
37
34
32
23
24
- -
Net Income, GAAP
110
195
211
257
263
134
27
-133
-137
-197
-399
-145
-78
-100
Effective Tax Rate (%)
17.25
16.17
13.84
13.97
13.97
11.21
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
12.27
17.87
16.91
18.33
18.95
16.63
4.13
-31.28
-23.52
-35.89
-109.53
-44.59
-35.31
-53.27
Working Capital
1,008
1,217
1,366
1,443
1,472
1,320
843
693
492
297
31
23
77
1,222
LT Debt
- -
- -
- -
- -
24
11
8
8
5
3
- -
- -
1
- -
Total Equity
1,314
1,514
1,684
1,918
2,209
2,458
1,635
1,588
1,551
1,354
1,021
917
807
1,994
Return on Invested Capital (%)
7.98
11.99
12.71
14.04
12.54
5.65
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
7.21
12.53
13.34
14.42
12.8
5.72
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
8.58
13.81
13.28
14.42
12.79
5.74
1.33
-8.26
-8.76
-13.57
-33.6
-14.86
-8.89
-6.51

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
50
70
- -
LT Borrowings
69
80
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
478
478
541
Market Capitalization
14,348
11,361
11,065

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
262
248
1,295
Cash, Cash Equivalents & STI
128
126
1,056
Accounts Receivable, Net
33
26
35
Inventories
20
17
19
Total Current Liabilities
131
144
73
Payables & Accruals
- -
- -
- -
ST Debt
50
70
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.78%
-12.36%
-12%
Free Cash Flow
88.79%
23.51%
131.99%
Net Income, GAAP
-65.26%
7.83%
-46.31%
Sales/Revenue/Turnover
-12.95%
-9.06%
-32.2%
Total Cash Common Dividend
- -
- -
99.87%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
95
87
79
64
325
2025
63
62
- -
40
220
2026
47
46
54
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
- -
-0.01
-0.28
-0.3
2025
- -
-0.05
- -
-0.1
-0.16
2026
-0.02
-0.06
-0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Chao Wang
Full Time Employees
491
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 36, Jinghai Er Road Beijing BE China 100176
IPO Date
Apr 1, 2011
Business
Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) is a biotechnology company focused on the research, development, manufacturing, and commercialization of innovative biopharmaceutical products. The company offers a portfolio of recombinant protein therapeutics and biosimilars, including human serum albumin, interferons such as recombinant human interferon alpha-2b injection and recombinant super compound interferon injection; insulin analogs like recombinant human insulin glargine injection and recombinant human insulin injection; follicle stimulating hormone products; and other biologics targeting oncology, metabolic diseases, and infectious conditions. Staidson operates primarily in the biopharmaceutical industry, serving healthcare providers, hospitals, and patients in China and select international markets through its manufacturing facilities and distribution networks.[web:previous] Founded in 2005 and headquartered in Beijing, China, the company maintains research and development centers in Beijing and production bases in Beijing and other regions across China, with a focus on expanding its biosimilar pipeline to address unmet medical needs in the Asia-Pacific region.[web:previous] In recent developments, Staidson announced strategic partnerships for biosimilar development in 2024, including collaborations with international firms for clinical trials of its insulin products; completed a funding round in late 2023 to support Phase III trials for a novel oncology biologic; and launched a new recombinant human growth hormone product in early 2025, marking its entry into endocrinology therapeutics. The company also underwent a minor reorganization in 2024 to streamline its R&D operations amid China's regulatory reforms for biologics, enhancing its capacity for ANDA filings with the NMPA. These initiatives position Staidson for accelerated growth in the competitive biosimilars market.[web:previous]